Home » Stocks » XAIR

Beyond Air, Inc. (XAIR)

Stock Price: $8.00 USD -0.21 (-2.56%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Pre-market: $7.98 -0.02 (-0.25%) Jul 26, 8:22 AM
Market Cap 175.21M
Revenue (ttm) 873,190
Net Income (ttm) -22.87M
Shares Out 20.76M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $8.00
Previous Close $8.21
Change ($) -0.21
Change (%) -2.56%
Day's Open 8.15
Day's Range 7.89 - 8.19
Day's Volume 279,048
52-Week Range 4.62 - 9.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Call scheduled for Tuesday, August 10th at 4:30 pm Eastern Time Call scheduled for Tuesday, August 10th at 4:30 pm Eastern Time

6 days ago - GlobeNewsWire

GARDEN CITY, N.Y., July 08, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...

2 weeks ago - GlobeNewsWire

Beyond Air (XAIR) has moved higher as of late, but there could definitely be trouble on the horizon for this company

4 weeks ago - Zacks Investment Research

Submitted first premarket approval (PMA) application in the Company's history to FDA for LungFit ® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial l...

1 month ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

GARDEN CITY, N.Y., May 26, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the...

2 months ago - GlobeNewsWire

Call scheduled for Thursday, June 10th at 4:30 pm Eastern Time Call scheduled for Thursday, June 10th at 4:30 pm Eastern Time

2 months ago - GlobeNewsWire

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Other stocks mentioned: AVRO, BYSI, FBIO
2 months ago - Zacks Investment Research

I nterim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit® PRO is well-tolerated with no...

2 months ago - GlobeNewsWire

Former Director of Healthcare Partnerships and External Relations at Linde plc brings 26 years of experience to Beyond Air Former Director of Healthcare Partnerships and External Relations at Linde plc ...

2 months ago - GlobeNewsWire

GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...

3 months ago - GlobeNewsWire

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients

5 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -6.45% and -25.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Beyond Air (NASDAQ:XAIR) moved lower in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 23.26% over the past year to ($0.33), which mis...

5 months ago - Benzinga

U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization

5 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time

6 months ago - GlobeNewsWire

Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval

7 months ago - Seeking Alpha

GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...

8 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q2 2021 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating im proved economics and safety in hospital setting

8 months ago - GlobeNewsWire

Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time

9 months ago - GlobeNewsWire

Patients with pneumonia caused by any virus, including SARS-CoV-2, will be considered for enrollment

9 months ago - GlobeNewsWire

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

9 months ago - GlobeNewsWire

In vitro data support development of nitric oxide as a potential coronavirus therapy that acts within hours

9 months ago - GlobeNewsWire

150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints

9 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...

9 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for...

10 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...

10 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for ...

10 months ago - GlobeNewsWire

Heterogeneity in M. abscessus susceptibility to NO

11 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2021 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Beyond Air Has Huge Long-Term Potential

11 months ago - Seeking Alpha

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

Conference call at 8:30 a.m. ET Conference call at 8:30 a.m. ET

1 year ago - GlobeNewsWire

Shares of Beyond Air Inc (NASDAQ:XAIR) rose by 2.9% from the previous closing price.

1 year ago - Benzinga

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q4 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints

1 year ago - GlobeNewsWire

Data demonstrate the ablation of solid tumors with nitric oxide

1 year ago - GlobeNewsWire

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

GARDEN CITY, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for ...

1 year ago - GlobeNewsWire

Anticipate study start in June 2020 Anticipate study start in June 2020

1 year ago - GlobeNewsWire

High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the key secondary endp...

1 year ago - GlobeNewsWire

GARDEN CITY, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for t...

1 year ago - GlobeNewsWire

Food and Drug Administration (FDA) agrees to a trial using  the LungFit ™ system to treat COVID-19 patients

1 year ago - GlobeNewsWire

Prepared to test LungFit™ BRO in COVID-19 patients in a clinical study starting in April pending FDA approval of recently submitted IDE (investigational device exemption) Prepared to test LungFit™ BRO i...

1 year ago - GlobeNewsWire

Beyond Air Inc. XAIR, +17.05% said Monday that it submitted an investigational device exemption to the Food and Drug Administration (FDA) as it seeks authority to market its nitric oxide device to treat...

1 year ago - Market Watch

Beyond Air: Buy The Stock Ahead Of March 5 Analyst Day

1 year ago - Seeking Alpha

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q3 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About XAIR

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Ther... [Read more...]

Industry
Medical Devices
CEO
Steven Lisi
Employees
41
Stock Exchange
NASDAQ
Ticker Symbol
XAIR
Full Company Profile

Financial Performance

In 2020, Beyond Air's revenue was $873,190, a decrease of -37.19% compared to the previous year's $1.39 million. Losses were -$22.87 million, 14.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Beyond Air stock is "Buy." The 12-month stock price forecast is 13.00, which is an increase of 62.50% from the latest price.

Price Target
$13.00
(62.50% upside)
Analyst Consensus: Buy